共 35 条
- [1] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialLANCET, 2020, 395 (10240): : 1835 - 1844Gutzmer, RalfStroyakovskiy, DaniilGogas, HelenRobert, CarolineLewis, KarlProtsenko, SvetlanaPereira, Rodrigo P.Eigentler, ThomasRutkowski, PiotrDemidov, LevManikhas, Georgy MoiseevichYan, YibingHuang, Kuan-ChiehUyei, AnneMcNally, VirginiaMcArthur, Grant A.Ascierto, Paolo A.
- [2] Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation- positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyLANCET ONCOLOGY, 2023, 24 (01): : 33 - 44Ascierto, Paolo A.Stroyakovskiy, DaniilGogas, HelenRobert, CarolineLewis, KarlProtsenko, SvetlanaPereira, Rodrigo P.Eigentler, ThomasRutkowski, PiotrDemidov, LevZhukova, NataliaSchachter, JacobYan, YibingCaro, IvorHertig, ChristianXue, ClorisKusters, LiekeMcArthur, Grant A.Gutzmer, Ralf
- [3] Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trialCANCER RESEARCH, 2020, 80 (16)McArthur, A.Stroyakovskiy, DaniilGogas, HelenRobert, CarolineLewis, KarlProtsenko, SvetlanaPereira, RodrigoEigentler, ThomasRutkowski, PiotrDemidov, LevManikhas, Georgy MoiseevichYan, YibingHuang, K. C.Uyei, AnneMcNally, VirginaGutzmer, RalfAscierto, Paolo
- [4] Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)McArthur, Grant A.Gutzmer, RalfStroyakovskiy, DaniilGogas, HelenRobert, CarolineProtsenko, SvetlanaPereira, Rodrigo PerezEigentler, ThomasRutkowski, PiotrDemidov, Lev V.Zhukova, Natalia V.Schachter, JacobYan, YibingCaro, IvorHertig, ChristianXue, ClorisKusters, LiekeAscierto, Paolo AntonioLewis, Karl D.
- [5] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialLANCET ONCOLOGY, 2018, 19 (04): : 510 - 520Maio, MicheleLewis, KarlDemidov, LevMandala, MarioBondarenko, IgorAscierto, Paolo A.Herbert, ChristopherMackiewicz, AndrzejRutkowski, PiotrGuminski, AlexanderGoodman, Grant R.Simmons, BrianYe, ChenglinYan, YibingSchadendorf, Dirk
- [6] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyJOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)Dummer, ReinhardWelti, MicheleRamelyte, Egle
- [7] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyJournal of Translational Medicine, 21Reinhard DummerMichèle WeltiEgle Ramelyte
- [8] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial (vol 19, pg 510, 2018)LANCET ONCOLOGY, 2018, 19 (04): : E184 - E184Maio, M.Lewis, K.Demidov, L.
- [9] coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Journal of Translational Medicine, 13 (Suppl 1)Paolo A AsciertoGrant A. McArthurBrigitte DrénoJames LarkinGabriella LiszkayMichele MaioMario MandalaLev DemidovDaniil StroyakovskiyLuc ThomasLuis de la Cruz-MerinoVictoria AtkinsonCaroline DutriauxClaus GarbeIlsung ChangStephen P. HackAntoni Ribas
- [10] TRILOGY/IMspire150: A phase 3, double-blinded, randomized study of atezolizumab (A) plus cobimetinib (C) combined with vemurafenib (V) vs. placebo plus C combined with v in previously untreated BRAFV600 mutation-positive patients with locally advanced or metastatic melanoma (NCT02908672/EudraCT 2016-002482-54)JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 46 - 47Ascierto, P.Lewis, K.McArthur, G.Rooney, I.McNally, V.